Analysis

New library building the LINC between pharmaceutical industry and academia

New library building the LINC between pharmaceutical industry and academia

July's top stories: Researchers found epithelial cells prevent Ebola, Mitsubishi agreed to buy NeuroDerm

July's top stories: Researchers found epithelial cells prevent Ebola, Mitsubishi agreed to buy NeuroDerm

Closing the US pharmaceutical industry’s growing skills gap

Closing the US pharmaceutical industry’s growing skills gap

PhRMA: resetting the conversation

PhRMA: resetting the conversation

Do healthcare cuts risk creating a ‘desert for innovation’ in the UK?

Do healthcare cuts risk creating a ‘desert for innovation’ in the UK?

Betting big on Gamma Delta T Cells

Betting big on Gamma Delta T Cells

Pharma Technology Focus – Issue 61

Pharma Technology Focus – Issue 61

Cystic fibrosis: searching for a breakthrough

Cystic fibrosis: searching for a breakthrough

US drug imports: a recipe for disaster?

US drug imports: a recipe for disaster?

Treating mononucleosis: why the mystery?

Treating mononucleosis: why the mystery?

Reforming paediatric cancer trials in Europe

Reforming paediatric cancer trials in Europe

Immuno-oncology: where to go in a packed field

Immuno-oncology: where to go in a packed field

June's top stories: Takeda and Biological E. collaborated, J&J completed Actelion acquisition

June's top stories: Takeda and Biological E. collaborated, J&J completed Actelion acquisition

Roundtable: discussing trends in contract manufacturing

Roundtable: discussing trends in contract manufacturing

Sealed with a kisspeptin: the clinical potential of the ‘love hormone’

Sealed with a kisspeptin: the clinical potential of the ‘love hormone’

Pharma Technology Focus – Issue 60

Pharma Technology Focus – Issue 60

Counting the cost of failure in drug development

Counting the cost of failure in drug development

Could a temperature-resistant vaccine spell the end for rabies and yellow fever?

Could a temperature-resistant vaccine spell the end for rabies and yellow fever?

The gene-silencing approach to cutting cholesterol

The gene-silencing approach to cutting cholesterol

May's top stories: Thermo Fisher Scientific buys Patheon for $7.2bn, AstraZeneca to sell rights for Seloken

May's top stories: Thermo Fisher Scientific buys Patheon for $7.2bn, AstraZeneca to sell rights for Seloken

Pooling resources for clinical trials

Pooling resources for clinical trials
cachename:Featurescachekey:rd-1665407042_727740091_rd-488908060_1460672566_ap1460672566_727740091_1125324024